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Background: The INFECT project aims to advance our under-
standing of the pathophysiological mechanisms in necrotizing soft
tissue infections (NSTIs). The INFECT observational study is part
of the INFECT project with the aim of studying the clinical profile
of patients with NSTIs and correlating these to patient-important
outcomes. With this protocol and statistical analysis plan we
describe the methods used to obtain data and the details of the
planned analyses.
Methods: The INFECT study is a multicentre, prospective obser-
vational cohort study. Patients with NSTIs are enrolled in five
Scandinavian hospitals, which are all referral centres for NSTIs.
The primary outcomes are the descriptive variables of the patients.
Secondary outcomes include identification of factors associated
with 90-day mortality and amputation; associations between
affected body part, maximum skin defect and Laboratory Risk
Indicator for Necrotizing Fasciitis (LRINEC) score and 90-day
mortality; 90-day mortality in patients with and without acute
kidney injury (AKI) and LRINEC score of six and above or below
six; and association between affected body part at arrival and
microbiological findings. Exploratory outcomes include univariate
analyses of baseline characteristics associations with 90-day mor-
tality. The statistical analyses will be conducted in accordance
with the predefined statistical analysis plan.
Conclusion: Necrotizing soft tissue infections result in severe
morbidity and mortality. The INFECT study will be the largest
prospective study in patients with NSTIs to date and will provide
important data for clinicians, researchers and policy makers on
the characteristics and outcomes of these patients.
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Necrotizing soft tissue infections (NSTIs) are
rare, but devastating diseases with high mortal-
ity rates, multiorgan impairment, amputation
and impaired quality of life among survivors.1,2
NSTIs may affect any layer of the soft tissue and
typically have a rapid progression. The aetiology
is often polymicrobial, but monomicrobial cases,
in particular with beta-haemolytic streptococci,
are also common.3 Managing patients with
NSTIs requires a multidisciplinary approach
including repeated surgery, antibiotics and
organ support. The treatments used vary
between centres.4 Due to low incidence rates,
only a few prospective cohort studies have been
performed, and knowledge has mainly been
derived from retrospective studies.
This observational study is part of the
‘Improving Outcome of Necrotizing Fasciitis:
Elucidation of Complex Host and Pathogen Sig-
natures that Dictate Severity of Tissue Infection
(INFECT)’ project – an investigator initiated
project to advance the understanding of the
pathophysiological mechanisms, diagnosis and
prognosis of NSTIs.5 The objectives of the
INFECT observational study are to describe the
clinical profile of patients with NSTI and to cor-
relate these to patient-important outcomes.
Methods
Trial design
INFECT is an international, prospective obser-
vational cohort study.
Setting
Patients are enrolled at five hospitals, which are
all referral centres for patients with NSTI:
Rigshospitalet, Copenhagen University Hospital,
Denmark; Karolinska University Hospital,
Solna, Sweden; Blekinge Hospital, Karlskrona,
Sweden; Sahlgrenska University Hospital,
Gothenburg, Sweden, and Haukeland University
Hospital, Bergen, Norway.
Population
We screen all adult patients (age ≥ 18 years)
admitted to one of the active centres with sus-
pected NSTI and include those with confirmed
NSTI as defined by perioperative tissue
characteristics, observed by the surgeon. The
diagnosis is based on signs as necrotic or deli-
quescent soft tissue with widespread undermin-
ing of the surrounding tissue.
Study size
A total of 400–500 patients are expected to be




The primary objective of the study was to
describe the population. The following data
have been registered and will be reported:
Baseline characteristics (first 24 h of intensive
care unit (ICU) admission)
1. Age (at time of diagnosis)
2. Sex
3. Weight before surgery; if not available then
best estimate
4. Body mass index
5. Comorbidities (y/n)
a. AIDS (HIV positive with clinical complica-
tions as Pneumocystis jiroveci pneumonia,
Kaposi’s sarcoma, lymphoma, tuberculosis
or toxoplasma infection)
b. Active malignancy
c. Metastatic carcinoma (proven metastasis
by surgery, C.T. scan or any other method)
d. Haematological cancer
e. Chronic obstructive pulmonary disease or
asthma
f. Cardiovascular disease (hypertension,
myocardial infarction, angina pectoris,
heart failure, stroke)
g. Peripheral vascular disease
h. Diabetes
i. Chronic kidney disease (s-creatinine > 100
before admission for NSTI or any kind of
dialysis)




m. Chronic wound or other skin disease
n. Immunodeficiency (any documented)
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o. No comorbidities
6. Preexisting conditions (y/n)
a. Previously affected by NSTI
b. Surgery before diagnosis of NSTI (any sur-
gery performed within the 4 weeks prior
to diagnosis)
c. Blunt trauma (a hit by a blunt object or a
fall within the 4 weeks prior to diagnosis)
d. Penetrating trauma (a hit by a sharp object
penetrating the skin within the 4 weeks
prior to diagnosis)
e. Use of IV drugs (either as a drug addict or
use of IV medication outside hospital set-
tings)
f. Use of immunosuppressing drugs (medica-
tion given for auto-immune or malignant
disease)
g. Use of steroids
h. Active smoking
i. Alcohol use above recommended limits
(above 14 units of alcohol per week for
females, above 21 for males)
7. Site of infection (y/n)
a. Head, neck and intrathoracic space
b. Upper extremity
c. Lower extremity
d. Ano-genital and abdominal area
8. Simplified acute physiology (SAPS) II score
9. Sequential organ failure assessment (SOFA)
score
10. Mechanical ventilation (mechanically
ventilated via a tube or continuously via a
mask)
11. Acute kidney injury (KDIGO stage 3)
12. Septic shock (use of vasopressor or inotropic
agents and lactate > 2 mmol/l)
13. Noradrenaline rate (highest)
Characteristics before diagnosis
1. Clinical characteristics














3. Gas on radiology
4. Laboratory Risk Indicator for Necrotizing
Fasciitis (LRINEC) score
Treatment characteristics, ICU day 1–7
1. Surgical management
a. Maximum skin defect observed during
surgery (%)
b. Number of operations
c. Time from admission to surgery (hours)
d. Amputation, any
2. Medical management
a. Antibiotics used in the ICU
i. Penicillin
ii. Dicloxacillin













b. Intravenous polyspecific immunoglobulin
G (IVIG)
c. Number of IVIG doses
d. Use of blood products
i. Erythrocytes
ii. Fresh frozen plasma
iii. Platelets
3. Supportive modalities
a. Mechanical ventilation during ICU admis-
sion
b. Renal replacement therapy during ICU
admission
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c. Use of vasopressor/inotrope during ICU
admission
d. Use of hyperbaric oxygenation (HBO) at
any time
e. Number of HBO sessions
Microbiological findings
1. Polymicrobial infection
a. Polymicrobial infection with presence of
beta-haemolytic streptococci
i. Polymicrobial infection with presence
of group A streptococcus
ii. Polymicrobial infection with presence
of group B streptococcus
iii. Polymicrobial infection with presence
of group C/G streptococcus
b. Polymicrobial infection with presence of
clostridium species
c. Polymicrobial infection with presence of
Staphylococcus aureus
d. Other polymicrobial infections
2. Monomicrobial infection
a. Monomicrobial infection with presence of
beta-haemolytic streptococci
i. Monomicrobial infection with pres-
ence of group A streptococcus
ii. Monomicrobial infection with pres-
ence of group B streptococcus
iii. Monomicrobial infection with pres-
ence of group C/G streptococcus
b. Monomicrobial infection with presence of
other streptococci
c. Monomicrobial infection with presence of
clostridium species
d. Monomicrobial infection with presence of
Staphylococcus aureus
e. Monomicrobial infection with presence of
anaerobic bacteria
f. Monomicrobial infection with presence of
aerobic gram-negative species
3. Patients with no bacteria detected
Follow-up
1. 30-day mortality (all-cause mortality)
2. 90-day mortality (all-cause mortality)
3. Days in the ICU (index admission)
4. Days on mechanical ventilation (index
admission)
5. Days on renal replacement therapy in the
90 days after inclusion (%)
6. Days alive and out of hospital in the 90 days
after inclusion (%)
Secondary outcomes
1. Identification of factors associated with 90-
day mortality
2. Identification of factors associated with
amputation of the extremities within ICU
stay
3. 90-day mortality in patients with AKI at
baseline vs. non-AKI
4. Association between affected body part at
arrival and microbiological findings
5. Association between affected body part at
arrival and 90-day mortality
6. Association between maximum skin defect
and 90-day mortality
7. Association between LRINEC score and 90-
day mortality
8. 90-day mortality in patients with a LRINEC
score ≥ 6 vs. < 6
Exploratory outcomes
Association between baseline variables and 90-
day mortality
Perspective
Protocols focusing specifically on the detailed
microbiological findings, streptococcal infec-
tions, HBO treatment, IVIG treatment, patients
with diabetes mellitus and long-term follow-up
including quality of life are being prepared.
Registered variables




Data will be presented as complete cases only
except for the following:
Acta Anaesthesiologica Scandinavica 62 (2018) 272–279
ª 2017 The Acta Anaesthesiologica Scandinavica Foundation. Published by John Wiley & Sons Ltd 275
INFECT PROTOCOL AND STATISTICAL ANALYSIS PLAN
SAPS II. If values from blood samples are miss-
ing, values from day 2 will be used.
SOFA score. If values from blood samples at day
1 are missing, values from day 2 will be used. If
values from blood samples at days 2–7 are miss-
ing, last observation carried forward will be
used. Due to the nature of eCRF, day 1 can vary
from 0 to 24 h. If day 1 is < 12 h, the worst
value from either day 1 or day 2 is used. The
SOFA score has been modified, as Glasgow
coma scale (GCS) is not included.
Kidney Disease, Improving Global Outcomes (KDIGO)
staging. KDIGO staging will be modified accord-
ing to the KDIGO serum creatinine criteria.7 Urine
output criteria will not be assessed. Preadmission
creatinine is not collected; the Modification of Diet
in Renal Disease (MDRD) equation will be used to
estimate the preadmission creatinine from a eGFR
of 75 ml/min per 1.73 m2 as recommended by the
KDIGO guidelines.7
Secondary outcomes
We will perform complete-case analyses. If the fre-
quency of missing data for a given analysis is more
than 5%, the analysis will be repeated using multi-
ple imputation based on chained equations
(MICE). The variables included in the multiple
imputation will be: the variables in the specific
analysis, age, SOFA score at day 1, presence of
haematological cancer, presence of diabetes, AKI at
baseline, shock at baseline, GAS as causative
microbiological agent and 90-day mortality. Lastly,
we will present unadjusted, non-imputed analysis.
General analytical principles
For all analyses, the level of statistical signifi-
cance (two sided) is 0.05. Correction for multi-
ple testing will be used when applicable.
Statistical analyses
Trial profile
The flow of patients will be displayed in a Con-
solidated Standard of Reporting Trials (CON-
SORT) diagram.
Primary outcome measure
The primary outcome will be presented as num-
ber/total number (percentage), median (IQR) or
mean (SD).
Secondary outcome measures
Identification of factors associated with 90-day
mortality. This will be done by logistic regression to
examine the crude and adjusted estimate. Inclusion
of covariates will be done in a single step (enter
modelling) to give the most conservative estimate.
The following covariates will be included:
1. Age8–11
2. AKI at baseline (KDIGO stage 3)9,12
3. Alcohol abuse (above 14 units of alcohol per
week for females, above 21 for males)13
4. BMI12
5. Diabetes mellitus12,13
6. Fluid input (total baseline input, ml/24 h)14
7. Group A streptococcus as probable causative
microorganism15,16
8. Haematological cancer or metastatic cancer17
9. Lactate (highest baseline lactate)18
10. Noradrenaline rate (highest baseline rate)9,19
11. Treating centre20,21
Age, fluid input, lactate and noradrenaline
rate will be categorized as linear variables, the
remaining as categorical variables. BMI will be
categorized according to WHO criteria. Results
will be presented as relative risk ratios includ-
ing 95% confidence intervals.
Identification of factors associated with amputation of
the extremities within ICU stay. Only patients with
NSTIs located on the extremities will be
included in the analysis. We will use the Cox
proportional hazards model with amputation of
the extremities within ICU stay as outcome and
SOFA score at day 1 and age as explanatory
variables. A variable selection algorithm will be
applied using the Bayesian Information Crite-
rion as selection criterion in a stepwise proce-
dure to select variables significantly associated
with amputation. In retrospective studies, bacte-
rial aetiology, shock, heart disease, diabetes
mellitus, cutaneous gangrene, skin necrosis and
high creatinine have been associated with limb
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amputation.8,16,22 However, the analyses were
performed in populations with NSTIs found ret-
rospectively. In order not to be biased by these
findings we will include all clinical variables.
Ninety-day mortality in patients with AKI at baseline
vs. non-AKI. Will be analysed by logistic regression
with 90-day mortality as outcome, AKI as explana-
tory variable and SOFA score at day 1 and age as
covariates. AKI will be defined as modified
KDIGO stage 3 (see Missing data section).
Association between affected body part at arrival and
microbiological findings. Will be performed by
Fisher’s exact test to test the association for each
bacterial group and subgroup with each body
part. P-values will be adjusted using the Ben-
jamin–Hochberg procedure controlling the false
discovery rate. The definitions of affected body
part and microbiological findings are given in
the Appendix S1.
Association between affected body part at arrival and
90-day mortality. Wewill build a logistic regression
model with the affected body part as explanatory
variable and the SOFA score and age as covariates.
The matrix design will be constructed to test the
association of a body part against the average asso-
ciation of all body parts instead of testing the asso-
ciation of a body part against a body part taken
arbitrary as a reference.
Association between maximum skin defect and 90-day
mortality. Will be analysed by logistic regression
with 90-day mortality as outcome and maximum
skin defect as explanatory variable. If a patient
is amputated, the size of the amputated area will
be used as maximum skin defect.
Association between LRINEC score and 90-day
mortality. Will be analysed by logistic regression
with 90-day mortality as outcome and LRINEC
score as explanatory variable.
Ninenty-day mortality in patients with a LRINEC score
≥ 6 vs. < 6. Will be analysed by logistic regres-
sion with 90-day mortality as outcome, LRINEC
score ≥ 6 as explanatory variable and SOFA
score at day 1 and age as covariates.
Explorative outcomes
Associations between baseline variables and 90-day
mortality. Identification of variables will be done
by univariate analyses using t-test for continu-
ous variables and Fisher’s exact test for dichoto-
mous variables. Variables with P-value < 0.10
are included in a multivariate analysis. All vari-
ables in the multivariate analysis will be
included in a single step. Results will be pre-
sented as relative risks including 95% confi-
dence intervals.
Data collection
Data will be entered into the web-based eCRF
by trial personnel. The trial database will be
established from the eCRF. In case of technical
difficulties, a paper CRF will be used.
Data handling and retention
Data will be handled according to the regula-
tions of the national data protection agencies.
All original records (including consent forms,
CRFs and relevant correspondences) will be
retained at trial sites for 15 years to allow
inspection by local authorities. The trial data-
base will be maintained for 15 years.
Ethics
The study will adhere to the Helsinki Declara-
tion and the national laws of the including
sites. The study is approved by the ethical
committees and data protection agencies in
each country of the participating sites. Due to
the severity of illness, patients are not able to
give informed consent prior to inclusion.
Informed consent will be obtained according to
national law. Oral information and written
information approved by the respective ethical
committees will be given to the consenting
party. Consent can be withdrawn at any time
without any consequences for the consenting
party or the patient.
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Approvals
The study is registered at ClinicalTrials.gov
(NCT01790698) and is approved by the Danish
Data Protection Agency (30-0900) and the fol-
lowing ethical committees: the Danish Ethical
Committees (1211709), the Swedish Ethical
Committee (Dnr 930-12) and the Regional Com-
mittee for Ethics in Medical Research (2012/
2227) in Western Norway.
Study management and organization
The study is part of INFECT project,5 led by
project coordinator Anna Norrby-Teglund. The
steering committee consists of Ole Hyldegaard,
Per Arnell, Ylva Karlsson, Michael Nekludov
and Steinar Skrede. Scientific and ethical advi-
sory boards can be found in the Appendix S1.
Local research teams are responsible for the
inclusion of patients 24/7.
Publication
We will report the study in accordance with the
STROBE reporting guidelines for observational
studies.23 The results of the study will be sub-
mitted for publication in an international peer-
reviewed journal.
Timeline
The first patient was included in February 2013
and last inclusion was in June 2017. After last
follow-up, data will be analysed and the paper
written and submitted for publication in late
2017.
Discussion
Necrotizing soft tissue infections occur world-
wide, but the underlying mechanisms are
poorly understood. This study will provide
important clinical data and may indicate factors
associated with certain outcomes. The strengths
of the study include the prospective design,
minimizing the risk of inclusion bias. Patients
are included in five different centres, making
the results more generalizable. To our knowl-
edge, this will be the largest cohort of patients
with NSTIs. The study is limited by its
observational design; no causative relations can
be made, only associations. Many analyses will
be performed, increasing the risk for chance
findings.
Conclusion
Necrotizing soft tissue infections result in sev-
ere morbidity and mortality. The INFECT study
will be the largest prospective study in patients
with NSTIs and will provide important data
for clinicians, researchers and policy makers on
the characteristics and outcomes of these
patients.
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